Ultragenyx Pharmaceutical Investors Alerted to Upcoming Class Action Deadline for Securities Fraud Claims
In a significant development for investors in Ultragenyx Pharmaceutical Inc., Kahn Swick & Foti, LLC, alongside its partner and former Louisiana Attorney General Charles C. Foti, Jr., has issued a crucial notice regarding an upcoming class action lawsuit. Investors are urged to take action due to the deadline for applications, set for April 6, 2026. The lawsuit specifically caters to individuals who may have suffered financial losses associated with alleged securities fraud that transpired between August 3, 2023, and December 26, 2025.
The class action lawsuit concerns the drastic impact of the company's disclosures in late December 2025, when Ultragenyx revealed the disappointing results from its Phase 3 Orbit and Cosmic studies of the drug setrusumab (UX143), aimed at treating Osteogenesis Imperfecta. These results indicated that the drug failed to statistically significantly reduce the rate of fractures in patients, which led the company to announce significant operational evaluations and expense reduction strategies in light of the unfavorable findings.
Following the announcement, Ultragenyx’s share price plummeted approximately 42%, dropping from $34.19 per share to $19.72 within a few days. This sudden decrease raised red flags for investors who may have been misled during the study trials, prompting the legal action. The lawsuit, officially titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097, seeks to hold Ultragenyx accountable for these alleged discrepancies.
Lewis Kahn, the managing partner at KSF, noted that this class action is particularly relevant for those investors who experienced losses during the specified timeframe. He emphasized the importance for affected parties to ensure their position in the case by reaching out to their firm to secure a place in the proceedings as a lead plaintiff, should they choose. However, Kahn reassured potential plaintiffs that participation in any eventual recovery does not require one to be a lead plaintiff.
Kahn Swick & Foti, LLC is well-regarded in the field of securities litigation, highlighted by their ranking among the top law firms nationally based on total settlement values. Their expertise lies in representing both institutional and individual investors who seek reparations for losses due to corporate fraud committed by publicly traded corporations, which in this case includes Ultragenyx.
For investors seeking to secure their claim or gather further information, Kahn Swick & Foti provides proactive support, including easy access through their platforms. Interested parties can contact Lewis Kahn at KSF toll-free or through their website to learn more about the lawsuit and the process for joining the class action.
As the April deadline swiftly approaches, investors must act promptly to safeguard their interests and seek potential reparations linked to their investments in Ultragenyx Pharmaceutical. The case stands as a reminder of the often-unforeseen risks in investing, particularly when corporate disclosures lead to drastic market fluctuations.
This latest legal initiative not only underscores the vulnerabilities that investors face within the biotech sector but also the resilience and vigilance required to navigate such complex landscapes efficiently. Investors wishing to join or inquire more can visit KSF's dedicated web page, which is designed for streamlined communication and information dissemination regarding this significant development.
The class action lawsuit concerns the drastic impact of the company's disclosures in late December 2025, when Ultragenyx revealed the disappointing results from its Phase 3 Orbit and Cosmic studies of the drug setrusumab (UX143), aimed at treating Osteogenesis Imperfecta. These results indicated that the drug failed to statistically significantly reduce the rate of fractures in patients, which led the company to announce significant operational evaluations and expense reduction strategies in light of the unfavorable findings.
Following the announcement, Ultragenyx’s share price plummeted approximately 42%, dropping from $34.19 per share to $19.72 within a few days. This sudden decrease raised red flags for investors who may have been misled during the study trials, prompting the legal action. The lawsuit, officially titled Steven Bailey v. Ultragenyx Pharmaceutical Inc., et al., No. 26-cv-01097, seeks to hold Ultragenyx accountable for these alleged discrepancies.
Lewis Kahn, the managing partner at KSF, noted that this class action is particularly relevant for those investors who experienced losses during the specified timeframe. He emphasized the importance for affected parties to ensure their position in the case by reaching out to their firm to secure a place in the proceedings as a lead plaintiff, should they choose. However, Kahn reassured potential plaintiffs that participation in any eventual recovery does not require one to be a lead plaintiff.
Kahn Swick & Foti, LLC is well-regarded in the field of securities litigation, highlighted by their ranking among the top law firms nationally based on total settlement values. Their expertise lies in representing both institutional and individual investors who seek reparations for losses due to corporate fraud committed by publicly traded corporations, which in this case includes Ultragenyx.
For investors seeking to secure their claim or gather further information, Kahn Swick & Foti provides proactive support, including easy access through their platforms. Interested parties can contact Lewis Kahn at KSF toll-free or through their website to learn more about the lawsuit and the process for joining the class action.
As the April deadline swiftly approaches, investors must act promptly to safeguard their interests and seek potential reparations linked to their investments in Ultragenyx Pharmaceutical. The case stands as a reminder of the often-unforeseen risks in investing, particularly when corporate disclosures lead to drastic market fluctuations.
This latest legal initiative not only underscores the vulnerabilities that investors face within the biotech sector but also the resilience and vigilance required to navigate such complex landscapes efficiently. Investors wishing to join or inquire more can visit KSF's dedicated web page, which is designed for streamlined communication and information dissemination regarding this significant development.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.